Interpretation of Chinese and American Guidelines for Diagnosis and Treatment of Thyroid Diseases During Pregnancy

Jiang Bohua; Tao Xinli; Ouyang Zhenbo; Yan Jiane

doi:doi:10.11648/j.sd.20210904.11

| Peer-Reviewed

Interpretation of Chinese and American Guidelines for Diagnosis and Treatment of Thyroid Diseases During Pregnancy

Jiang Bohua, Tao Xinli, Ouyang Zhenbo, Yan Jiane

Published in Science Discovery (Volume 9, Issue 4)

Received: 6 April 2021 Accepted: Published: 24 May 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

More and more studies have found that thyrotoxicosis and hypothyroidism are related to adverse pregnancy outcomes, and maternal thyroid diseases also have a certain impact on fetal development. Drugs used to treat maternal hyperthyroidism can pass through the placenta and affect fetal thyroid development and thyroid function, and may cause fetal development malformations . Due to the lack of in-depth knowledge of this disease, timely screening, medical consultation and treatment rates for thyroid diseases during pregnancy are relatively low. Like this, if the treatment is not timely, it may cause irreversible effects on the pregnancy process and the fetus, such as increasing the risk of high blood pressure during pregnancy, miscarriage, premature delivery, low birth weight, stillbirth, thyroid crisis and maternal congestive heart failure, and impairing the neurological and intellectual development of offspring. This article intends to provide a reference for clinicians in the standardized diagnosis and treatment of thyroid diseases during pregnancy and postpartum through a comparative analysis of the latest guidelines for the diagnosis and treatment of thyroid diseases during pregnancy in China and the United States in 2020. It is hoped that through this article, various related complications and risks of mothers, fetuses and pregnancy caused by abnormal thyroid function will be reduced, and the quality of the population will be improved.

Published in	Science Discovery (Volume 9, Issue 4)
DOI	10.11648/j.sd.20210904.11
Page(s)	133-138
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Pregnancy, Thyroid Disease, Diagnosis and Treatment Norms, Guidelines

References

[1]	De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2012, 97(8): 2543-2565.
[2]	《妊娠和产后甲状腺疾病诊治指南》编撰委员会, 中华医学会内分泌学分会, 中华医学会围产医学分会. 妊娠和产后甲状腺疾病诊治指南(第2版). 中华内分泌代谢杂志, 2019, 35(8): 636-665.
[3]	Thyroid Disease in Pregnancy: ACOG Practice Bulletin, Number 223. Obstet Gynecol, 2020, 135(6): e261-e274.
[4]	Vannucchi G, Covelli D, Vigo B, et al. Thyroid volume and serum calcitonin changes during pregnancy. Journal of Endocrinological Investigation, 2017, 40(7): 727-732.
[5]	Li C, Shan Z, Mao J, et al. Assessment of thyroid function during first-trimester pregnancy: what is the rational upper limit of serum TSH during the first trimester in Chinese pregnant women? J Clin Endocrinol Metab, 2014, 99(1): 73-79.
[6]	Cleary-Goldman J, Malone FD, Lambert-Messerlian G, et al. Maternal thyroid hypofunction and pregnancy outcome. Obstet Gynecol, 2008, 112(1): 85-92.
[7]	Hales C, Taylor PN, Channon S, et al. Controlled Antenatal Thyroid Screening II: Effect of Treating Maternal Suboptimal Thyroid Function on Child Cognition. J Clin Endocrinol Metab, 2018, 103(4): 1583-1591.
[8]	Zhang Y, Wang H, Pan X, et al. Patients with subclinical hypothyroidism before 20 weeks of pregnancy have a higher risk of miscarriage: A systematic review and meta-analysis. PLoS One, 2017, 12(4): e0175708.
[9]	Shi X, Han C, Li C, et al. Optimal and safe upper limits of iodine intake for early pregnancy in iodine-sufficient regions: a cross-sectional study of 7190 pregnant women in China. J Clin Endocrinol Metab, 2015, 100(4): 1630-1638.
[10]	Teng X, Shan Z, Li C, et al. Iron Deficiency May Predict Greater Risk for Hypothyroxinemia: A Retrospective Cohort Study of Pregnant Women in China. Thyroid, 2018, 28(8): 968-975.
[11]	Thangaratinam S, Tan A, Knox E, et al. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. Bmj, 2011, 342: d2616.
[12]	Andersen SL, Olsen J, Laurberg P. Foetal programming by maternal thyroid disease. Clinical Endocrinology, 2015, 83(6):751-758.
[13]	Korevaar TIM, Muetzel R, Medici M, et al. Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study. Lancet Diabetes & Endocrinology, 2016, 4(1):35-43.
[14]	Donnelly MA, Wood C, Casey B, et al. Early severe fetal Graves disease in a mother after thyroid ablation and thyroidectomy. Obstet Gynecol, 2015, 125(5): 1059-1062.
[15]	Andersen SL, Olsen J, Wu CS, et al. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab, 2013, 98(11): 4373-4381.
[16]	Seo GH, Kim TH, Chung JH. Antithyroid Drugs and Congenital Malformations: A Nationwide Korean Cohort Study. Ann Intern Med, 2018, 168(6): 405-413.
[17]	Maurizio C, Di GE, Matteo C, et al. Treatment of Hyperthyroidism in Pregnancy and Birth Defects. Journal of Clinical Endocrinology & Metabolism, 2010, (11): 11.
[18]	Ai Y, JaedukYoshimura N, Takuhiro Y, et al. Treatment of Graves' Disease with Antithyroid Drugs in the First Trimester of Pregnancy and the Prevalence of Congenital Malformation. Journal of Clinical Endocrinology & Metabolism, 2012, (7): 7.
[19]	Tudela CM, Casey BM, Mcintire DD, et al. Relationship of Subclinical Thyroid Disease to the Incidence of Gestational Diabetes. Obstetrics & Gynecology, 2012, 119(5): 983-988.
[20]	Wilson KL. Subclinical thyroid disease and the incidence of hypertension in pregnancy. Obstetrics & Gynecology, 2012, 119(1): 315-320.
[21]	Casey BM, Dashe JS, Wells CE, et al. Subclinical Hyperthyroidism and Pregnancy Outcomes. Obstetrics & Gynecology, 2006, 107(2, Part 1): 337-341.
[22]	Kung AWC, Chau MT, Lao TT, et al. The effect of pregnancy on thyroid nodule formation. Journal of Clinical Endocrinology & Metabolism, 2002, 87(3): 1010-1014.
[23]	Smith LH, Danielsen B, Allen ME, et al. Cancer associated with obstetric delivery: results of linkage with the California cancer registry. American Journal of Obstetrics & Gynecology, 2003, 189(4): 1128-1135.
[24]	Vaidya B, Anthony S, Bilous M, et al. Detection of thyroid dysfunction in early pregnancy: Universal screening or targeted high-risk case finding? J Clin Endocrinol Metab, 2007, 92(1): 203-207.
[25]	Wang W, Teng W, Shan Z, et al. The prevalence of thyroid disorders during early pregnancy in China: the benefits of universal screening in the first trimester of pregnancy. European Journal of Endocrinology, 2011, 164(2): 263-268.
[26]	Hong, Yang, Minglong, et al. Screening Strategies for Thyroid Disorders in the First and Second Trimester of Pregnancy in China. Plos One, 2014,9(6):e99611.
[27]	Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid, 2012, 22(12): 1200-1235.
[28]	Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid, 2017, 27(3): 315-389.

Cite This Article

Plain Text BibTeX RIS

APA Style

Jiang Bohua, Tao Xinli, Ouyang Zhenbo, Yan Jiane. (2021). Interpretation of Chinese and American Guidelines for Diagnosis and Treatment of Thyroid Diseases During Pregnancy. Science Discovery, 9(4), 133-138. https://doi.org/10.11648/j.sd.20210904.11

Copy | Download

ACS Style

Jiang Bohua; Tao Xinli; Ouyang Zhenbo; Yan Jiane. Interpretation of Chinese and American Guidelines for Diagnosis and Treatment of Thyroid Diseases During Pregnancy. Sci. Discov. 2021, 9(4), 133-138. doi: 10.11648/j.sd.20210904.11

Copy | Download

AMA Style

Jiang Bohua, Tao Xinli, Ouyang Zhenbo, Yan Jiane. Interpretation of Chinese and American Guidelines for Diagnosis and Treatment of Thyroid Diseases During Pregnancy. Sci Discov. 2021;9(4):133-138. doi: 10.11648/j.sd.20210904.11

Copy | Download

@article{10.11648/j.sd.20210904.11,
  author = {Jiang Bohua and Tao Xinli and Ouyang Zhenbo and Yan Jiane},
  title = {Interpretation of Chinese and American Guidelines for Diagnosis and Treatment of Thyroid Diseases During Pregnancy},
  journal = {Science Discovery},
  volume = {9},
  number = {4},
  pages = {133-138},
  doi = {10.11648/j.sd.20210904.11},
  url = {https://doi.org/10.11648/j.sd.20210904.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20210904.11},
  abstract = {More and more studies have found that thyrotoxicosis and hypothyroidism are related to adverse pregnancy outcomes, and maternal thyroid diseases also have a certain impact on fetal development. Drugs used to treat maternal hyperthyroidism can pass through the placenta and affect fetal thyroid development and thyroid function, and may cause fetal development malformations . Due to the lack of in-depth knowledge of this disease, timely screening, medical consultation and treatment rates for thyroid diseases during pregnancy are relatively low. Like this, if the treatment is not timely, it may cause irreversible effects on the pregnancy process and the fetus, such as increasing the risk of high blood pressure during pregnancy, miscarriage, premature delivery, low birth weight, stillbirth, thyroid crisis and maternal congestive heart failure, and impairing the neurological and intellectual development of offspring. This article intends to provide a reference for clinicians in the standardized diagnosis and treatment of thyroid diseases during pregnancy and postpartum through a comparative analysis of the latest guidelines for the diagnosis and treatment of thyroid diseases during pregnancy in China and the United States in 2020. It is hoped that through this article, various related complications and risks of mothers, fetuses and pregnancy caused by abnormal thyroid function will be reduced, and the quality of the population will be improved.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Interpretation of Chinese and American Guidelines for Diagnosis and Treatment of Thyroid Diseases During Pregnancy
AU  - Jiang Bohua
AU  - Tao Xinli
AU  - Ouyang Zhenbo
AU  - Yan Jiane
Y1  - 2021/05/24
PY  - 2021
N1  - https://doi.org/10.11648/j.sd.20210904.11
DO  - 10.11648/j.sd.20210904.11
T2  - Science Discovery
JF  - Science Discovery
JO  - Science Discovery
SP  - 133
EP  - 138
PB  - Science Publishing Group
SN  - 2331-0650
UR  - https://doi.org/10.11648/j.sd.20210904.11
AB  - More and more studies have found that thyrotoxicosis and hypothyroidism are related to adverse pregnancy outcomes, and maternal thyroid diseases also have a certain impact on fetal development. Drugs used to treat maternal hyperthyroidism can pass through the placenta and affect fetal thyroid development and thyroid function, and may cause fetal development malformations . Due to the lack of in-depth knowledge of this disease, timely screening, medical consultation and treatment rates for thyroid diseases during pregnancy are relatively low. Like this, if the treatment is not timely, it may cause irreversible effects on the pregnancy process and the fetus, such as increasing the risk of high blood pressure during pregnancy, miscarriage, premature delivery, low birth weight, stillbirth, thyroid crisis and maternal congestive heart failure, and impairing the neurological and intellectual development of offspring. This article intends to provide a reference for clinicians in the standardized diagnosis and treatment of thyroid diseases during pregnancy and postpartum through a comparative analysis of the latest guidelines for the diagnosis and treatment of thyroid diseases during pregnancy in China and the United States in 2020. It is hoped that through this article, various related complications and risks of mothers, fetuses and pregnancy caused by abnormal thyroid function will be reduced, and the quality of the population will be improved.
VL  - 9
IS  - 4
ER  -

Copy | Download

Author Information

Jiang Bohua

Changsha County Maternal and Child Health Care Hospital, Changsha, China
Tao Xinli

Department of Gynecology, Xiangzhou District People's Hospital of Xiangyang City, Xiangyang, China
Ouyang Zhenbo

Department of Gynecology, Second People's Hospital of Guangdong Province, Guangzhou, China
Yan Jiane

Changsha County Maternal and Child Health Care Hospital, Changsha, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Jiang Bohua, Tao Xinli, Ouyang Zhenbo, Yan Jiane. (2021). Interpretation of Chinese and American Guidelines for Diagnosis and Treatment of Thyroid Diseases During Pregnancy. Science Discovery, 9(4), 133-138. https://doi.org/10.11648/j.sd.20210904.11

Copy | Download

ACS Style

Jiang Bohua; Tao Xinli; Ouyang Zhenbo; Yan Jiane. Interpretation of Chinese and American Guidelines for Diagnosis and Treatment of Thyroid Diseases During Pregnancy. Sci. Discov. 2021, 9(4), 133-138. doi: 10.11648/j.sd.20210904.11

Copy | Download

AMA Style

Jiang Bohua, Tao Xinli, Ouyang Zhenbo, Yan Jiane. Interpretation of Chinese and American Guidelines for Diagnosis and Treatment of Thyroid Diseases During Pregnancy. Sci Discov. 2021;9(4):133-138. doi: 10.11648/j.sd.20210904.11

Copy | Download

@article{10.11648/j.sd.20210904.11,
  author = {Jiang Bohua and Tao Xinli and Ouyang Zhenbo and Yan Jiane},
  title = {Interpretation of Chinese and American Guidelines for Diagnosis and Treatment of Thyroid Diseases During Pregnancy},
  journal = {Science Discovery},
  volume = {9},
  number = {4},
  pages = {133-138},
  doi = {10.11648/j.sd.20210904.11},
  url = {https://doi.org/10.11648/j.sd.20210904.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20210904.11},
  abstract = {More and more studies have found that thyrotoxicosis and hypothyroidism are related to adverse pregnancy outcomes, and maternal thyroid diseases also have a certain impact on fetal development. Drugs used to treat maternal hyperthyroidism can pass through the placenta and affect fetal thyroid development and thyroid function, and may cause fetal development malformations . Due to the lack of in-depth knowledge of this disease, timely screening, medical consultation and treatment rates for thyroid diseases during pregnancy are relatively low. Like this, if the treatment is not timely, it may cause irreversible effects on the pregnancy process and the fetus, such as increasing the risk of high blood pressure during pregnancy, miscarriage, premature delivery, low birth weight, stillbirth, thyroid crisis and maternal congestive heart failure, and impairing the neurological and intellectual development of offspring. This article intends to provide a reference for clinicians in the standardized diagnosis and treatment of thyroid diseases during pregnancy and postpartum through a comparative analysis of the latest guidelines for the diagnosis and treatment of thyroid diseases during pregnancy in China and the United States in 2020. It is hoped that through this article, various related complications and risks of mothers, fetuses and pregnancy caused by abnormal thyroid function will be reduced, and the quality of the population will be improved.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Interpretation of Chinese and American Guidelines for Diagnosis and Treatment of Thyroid Diseases During Pregnancy
AU  - Jiang Bohua
AU  - Tao Xinli
AU  - Ouyang Zhenbo
AU  - Yan Jiane
Y1  - 2021/05/24
PY  - 2021
N1  - https://doi.org/10.11648/j.sd.20210904.11
DO  - 10.11648/j.sd.20210904.11
T2  - Science Discovery
JF  - Science Discovery
JO  - Science Discovery
SP  - 133
EP  - 138
PB  - Science Publishing Group
SN  - 2331-0650
UR  - https://doi.org/10.11648/j.sd.20210904.11
AB  - More and more studies have found that thyrotoxicosis and hypothyroidism are related to adverse pregnancy outcomes, and maternal thyroid diseases also have a certain impact on fetal development. Drugs used to treat maternal hyperthyroidism can pass through the placenta and affect fetal thyroid development and thyroid function, and may cause fetal development malformations . Due to the lack of in-depth knowledge of this disease, timely screening, medical consultation and treatment rates for thyroid diseases during pregnancy are relatively low. Like this, if the treatment is not timely, it may cause irreversible effects on the pregnancy process and the fetus, such as increasing the risk of high blood pressure during pregnancy, miscarriage, premature delivery, low birth weight, stillbirth, thyroid crisis and maternal congestive heart failure, and impairing the neurological and intellectual development of offspring. This article intends to provide a reference for clinicians in the standardized diagnosis and treatment of thyroid diseases during pregnancy and postpartum through a comparative analysis of the latest guidelines for the diagnosis and treatment of thyroid diseases during pregnancy in China and the United States in 2020. It is hoped that through this article, various related complications and risks of mothers, fetuses and pregnancy caused by abnormal thyroid function will be reduced, and the quality of the population will be improved.
VL  - 9
IS  - 4
ER  -

Copy | Download